{"filings":[{"id":2216840,"accession_number":"0001055726-26-000024","cik":1055726,"company_name":"INOVIO PHARMACEUTICALS, INC.","ticker":"INO","form_type":"8-K","filed_at":"2026-08-12T20:07:49+00:00","items":["2.02","9.01"],"status":"ready","headline":"INOVIO reports Q2 2026 net loss of $6.0M; INO-3107 PDUFA on Oct 30, 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $6.0M ($0.07/share) vs $23.5M ($0.61) in Q2 2025; includes $13.9M non-cash warrant gain.","Cash and investments $36.7M at June 30, 2026, plus $18.3M from July offering; runway into late Q1 2027.","FDA review of INO-3107 BLA continues; PDUFA target action date October 30, 2026; commercial launch prep ongoing.","ApolloBio reported positive Phase 3 topline for VGX-3100 in China for cervical dysplasia.","Operating expenses fell to $18.6M from $23.1M YoY; R&D down to $10.8M."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.34,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2026-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":106543834.404,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1977197,"accession_number":"0001193125-26-326785","cik":1055726,"company_name":"INOVIO PHARMACEUTICALS, INC.","ticker":"INO","form_type":"8-K","filed_at":"2026-07-31T11:23:30+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Inovio prices $20M public offering of common stock and warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offering of 21,052,632 shares and warrants to purchase up to 42,105,264 shares at $1.10 exercise price.","Combined price $0.95 per share and warrant; gross proceeds $20M, net proceeds ~$18.3M.","Underwriter Piper Sandler; option exercised for additional warrants to buy 6,315,788 shares.","Closing expected on or about July 31, 2026, subject to customary conditions.","Proceeds intended for general corporate purposes; no specific use disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":106543834.404,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1940480,"accession_number":"0001193125-26-323628","cik":1055726,"company_name":"INOVIO PHARMACEUTICALS, INC.","ticker":"INO","form_type":"8-K","filed_at":"2026-07-29T20:03:42+00:00","items":["2.02"],"status":"ready","headline":"Inovio reports preliminary Q2 2026 cash balance of $36.7M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Cash and cash equivalents estimated at $36.7 million as of June 30, 2026.","Preliminary unaudited data subject to completion of financial closing procedures.","No other financial results or guidance provided in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":106543834.404,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":554160,"accession_number":"0001193125-26-232524","cik":1055726,"company_name":"INOVIO PHARMACEUTICALS, INC.","ticker":"INO","form_type":"8-K","filed_at":"2026-05-20T20:01:49+00:00","items":["5.03","5.07","9.01"],"status":"ready","headline":"Inovio stockholders elect eight directors, approve omnibus plan at annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All eight director nominees elected; votes for ranged from 22.3M to 22.7M, with 17.1M broker non-votes.","Ratification of Ernst & Young as auditor for 2026 approved: 39.3M for, 1.2M against, 143k abstain.","Non-binding advisory vote on NEO compensation passed with 21.5M for, 1.6M against, 471k abstain.","Amendment and restatement of 2023 Omnibus Incentive Plan approved with 21.6M for, 1.5M against.","Board adopted bylaw amendment establishing Lead Independent Director role and clarifying Chairman duties."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":106543834.404,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":68084,"accession_number":"0001055726-26-000019","cik":1055726,"company_name":"INOVIO PHARMACEUTICALS, INC.","ticker":"INO","form_type":"8-K","filed_at":"2026-05-13T20:07:44+00:00","items":["2.02","9.01"],"status":"ready","headline":"Inovio Q1 net loss $19.7M ($0.28/shr); cash runway into Q1 2027 beyond Oct PDUFA","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $19.7M, flat YoY; diluted EPS ($0.28) vs ($0.51) due to fewer shares.","Revenue not reported (pre-revenue biotech); R&D spend $14.1M (-12% YoY), G&A $7.9M (-12%).","Cash & equivalents $37.7M at Mar 31, plus $16M from April offering; expects ops into Q1 2027.","FDA reviewing INO-3107 BLA under accelerated approval; PDUFA date Oct 30, 2026.","Collaboration with Akeso to test INO-5412 + cadonilimab in GBM in Dana-Farber INSIGhT trial."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.28,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":106543834.404,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":90953,"accession_number":"0001193125-26-142885","cik":1055726,"company_name":"INOVIO PHARMACEUTICALS, INC.","ticker":"INO","form_type":"8-K","filed_at":"2026-04-06T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Inovio prices $17.5M public offering of 12.5M shares and warrants; net proceeds ~$16M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["12.5M shares and Series A/B warrants (each exercisable for 1 share at $1.40) priced at $1.40 per unit.","Gross proceeds $17.5M; net proceeds ~$16M after underwriting discounts and expenses.","Underwriters granted 30-day option to buy up to 1.875M additional shares and warrants.","Series A warrants expire in 1 year, Series B warrants in 5 years; beneficial ownership cap 4.99%.","Closing expected April 6, 2026; Piper Sandler sole book-running manager."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":106543834.404,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":90952,"accession_number":"0001193125-26-138870","cik":1055726,"company_name":"INOVIO PHARMACEUTICALS, INC.","ticker":"INO","form_type":"8-K","filed_at":"2026-04-02T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Inovio suspends ATM prospectus; raised $3.2M from 1.3M shares under program","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["On April 1, 2026, Inovio notified Oppenheimer of suspension and termination of the ATM prospectus from August 13, 2024.","No further sales under the ATM program until a new prospectus is filed; the Sales Agreement remains in effect.","As of April 1, 2026, Inovio had sold 1,319,644 shares for gross proceeds of $3.2 million under the ATM program."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":106543834.404,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":100816,"accession_number":"0001055726-26-000009","cik":1055726,"company_name":"INOVIO PHARMACEUTICALS, INC.","ticker":"INO","form_type":"8-K","filed_at":"2026-03-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Inovio reports FY 2025 net loss $84.9M; INO-3107 BLA accepted with PDUFA Oct 30, 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2025 net income $3.8M ($0.06 basic EPS) mainly from $21.2M non-cash warrant gain; FY net loss $84.9M ($1.81/share).","Cash, equivalents & short-term investments $58.5M as of Dec 31, 2025; estimated runway into Q4 2026 with Q1 2026 burn ~$22M.","FDA accepted BLA for INO-3107 under accelerated approval program; PDUFA date Oct 30, 2026; FDA questioned accelerated eligibility.","Published INO-3107 Phase 1/2 and long-term data in Nature Communications and The Laryngoscope showing reduced surgeries.","Entered clinical trial collaboration with Akeso to evaluate INO-5412 + cadonilimab for glioblastoma in Dana-Farber INSIGhT trial."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":106543834.404,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":100815,"accession_number":"0001193125-26-024431","cik":1055726,"company_name":"INOVIO PHARMACEUTICALS, INC.","ticker":"INO","form_type":"8-K","filed_at":"2026-01-27T23:59:59+00:00","items":["1.01","3.03","9.01"],"status":"ready","headline":"Inovio extends Series A Warrant expiration to March 31, 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Amendment extends expiration of Series A Warrants (up to 13,564,268 shares) from Jan 28, 2026 to March 31, 2026.","Warrants issued in July 2025 public offering; exercise price $1.75/share (pre-funded at $0.001).","Original expiration was 30 days after FDA BLA acceptance for INO-3107; extension provides additional exercise window.","All other warrant terms remain unchanged."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":106543834.404,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":117118,"accession_number":"0001193125-25-332322","cik":1055726,"company_name":"INOVIO PHARMACEUTICALS, INC.","ticker":"INO","form_type":"8-K","filed_at":"2025-12-29T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"FDA accepts INOVIO's BLA for INO-3107; standard review, PDUFA Oct 2026, but flags accelerated approval issue","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["BLA accepted for review; FDA classified as standard; no advisory committee planned.","PDUFA goal date October 30, 2026.","FDA preliminary conclusion: inadequate info to justify accelerated approval eligibility.","Company to request meeting with FDA to discuss accelerated approval; not pursuing traditional pathway.","INO-3107 is investigational immunotherapy for recurrent respiratory papillomatosis (RRP) in adults."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":106543834.404,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":117117,"accession_number":"0001193125-25-275721","cik":1055726,"company_name":"INOVIO PHARMACEUTICALS, INC.","ticker":"INO","form_type":"8-K","filed_at":"2025-11-12T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Inovio prices 15.1M share offering at $1.90, net proceeds ~$26.5M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Inovio sold 13.158M shares at $1.90; underwriters exercised option for 1.974M additional shares.","Net proceeds expected ~$26.5M after discounts and expenses; closing November 12, 2025.","Piper Sandler & Co. acted as sole book-running manager for the offering.","Offering made under effective shelf registration statement; all shares sold by Inovio."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":106543834.404,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":117116,"accession_number":"0001055726-25-000064","cik":1055726,"company_name":"INOVIO PHARMACEUTICALS, INC.","ticker":"INO","form_type":"8-K","filed_at":"2025-11-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"INOVIO completes rolling BLA for INO-3107; Q3 net loss $45.5M, cash runway into Q2 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Completed rolling BLA submission for INO-3107 (RRP); priority review requested; potential FDA decision mid-2026.","Net loss of $45.5M ($0.87/share) versus $25.2M loss a year ago; operating loss improved to $21.2M from $27.3M.","Cash and short-term investments $50.8M as of Sept 30, 2025; estimated runway into Q2 2026 with Q4 cash burn ~$22M.","R&D expenses fell to $13.3M from $18.7M; G&A expenses $7.9M down from $8.6M year-over-year.","Phase 1 DMAb data for COVID-19 published in Nature Medicine; demonstrated durable antibody expression in humans."],"consensus_eps_estimate":-0.4274,"consensus_eps_actual":-2.12,"consensus_revenue_estimate":null,"consensus_revenue_actual":65343.0,"consensus_period":"2025-Q3","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":106543834.404,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":133567,"accession_number":"0001055726-25-000056","cik":1055726,"company_name":"INOVIO PHARMACEUTICALS, INC.","ticker":"INO","form_type":"8-K","filed_at":"2025-08-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Inovio Q2 net loss narrows to $23.5M; BLA for INO-3107 on track for 2H25 submission","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $23.5M ($0.61/share) vs $32.2M ($1.19/share) YoY; total operating expenses $23.1M down from $33.3M.","Completed CELLECTRA 5PSP device DV testing; requested rolling BLA submission for INO-3107 by year end.","Cash, cash equivalents, and short-term investments $47.5M at June 30; plus $22.5M from July offering, supporting ops into Q2 2026.","Long-term INO-3107 data published: 86% of patients had 50-100% reduction in surgeries by Year 2; mean surgeries reduced from 4.1 to 0.9.","R&D expenses fell to $14.5M from $23.1M, reflecting lower drug manufacturing and clinical costs."],"consensus_eps_estimate":-0.6153,"consensus_eps_actual":-1.12,"consensus_revenue_estimate":null,"consensus_revenue_actual":65343.0,"consensus_period":"2025-Q2","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":106543834.404,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":133566,"accession_number":"0001193125-25-155830","cik":1055726,"company_name":"INOVIO PHARMACEUTICALS, INC.","ticker":"INO","form_type":"8-K","filed_at":"2025-07-07T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Inovio prices $25M public offering of common stock and warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of $25M from 14,285,715 shares and accompanying Series A/B warrants at $1.75/unit.","Net proceeds expected ~$22.5M after underwriting discounts and expenses; closing on July 7, 2025.","Underwriters have 30-day option for up to 2,142,857 additional shares and warrants.","Series A warrants expire 12 months from issuance or 30 days after FDA acceptance of BLA for INO-3107.","Series B warrants expire 5 years; Piper Sandler sole book-runner, Oppenheimer passive bookrunner."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":106543834.404,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":150244,"accession_number":"0001055726-25-000045","cik":1055726,"company_name":"INOVIO PHARMACEUTICALS, INC.","ticker":"INO","form_type":"8-K","filed_at":"2025-05-22T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Inovio shareholders elect eight directors, ratify auditor, approve executive compensation and equity plan","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Eight directors elected: each received 7.3M-8.4M votes for, 0.6M-1.7M withheld, 11M broker non-votes.","Ernst & Young ratified as auditor for FY2025: 19.3M for, 0.6M against, 0.2M abstain.","Advisory say-on-pay passed: 7.9M for, 1.1M against, 0.2M abstain, 11M broker non-votes.","Amendment and restatement of 2023 Omnibus Incentive Plan approved: 7.8M for, 1.2M against, 0.1M abstain."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":106543834.404,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":150243,"accession_number":"0001055726-25-000027","cik":1055726,"company_name":"INOVIO PHARMACEUTICALS, INC.","ticker":"INO","form_type":"8-K","filed_at":"2025-05-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Inovio Q1 net loss narrows to $19.7M; BLA submission for INO-3107 on track for mid-2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss narrowed to $19.7M ($0.51/share) from $30.5M ($1.31) in Q1 2024.","Cash and short-term investments $68.4M as of Mar 31, 2025, down from $94.1M at Dec 31, 2024.","On track to begin rolling BLA submission for INO-3107 (RRP) in mid-2025; FDA acceptance targeted by year-end.","DMAb Phase 1 trial: 100% of participants (24/24) at week 72 maintained antibody levels; no anti-drug antibodies.","R&D expenses decreased to $16.1M from $20.9M; net cash burn guidance ~$22M for Q2 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.51,"consensus_revenue_estimate":null,"consensus_revenue_actual":65343.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":106543834.404,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":169252,"accession_number":"0001055726-25-000013","cik":1055726,"company_name":"INOVIO PHARMACEUTICALS, INC.","ticker":"INO","form_type":"8-K","filed_at":"2025-03-18T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Inovio reports FY2024 net loss $107.3M; on track for INO-3107 BLA submission mid-2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $19.4M Q4 ($0.65/share) and $107.3M FY ($3.95/share), narrower than 2023's $135.1M.","Cash, equivalents & investments $94.1M at Dec 31, 2024, down from $145.3M at Dec 31, 2023.","BLA for INO-3107 (RRP) on track for rolling submission mid-2025; device verification testing complete H1 2025.","DMAb interim data: 100% of participants (24/24) maintained antibody levels at week 72; no anti-drug antibodies.","Raised >$72M from ATM and two equity offerings in 2024; cash runway into Q1 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":106543834.404,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":186289,"accession_number":"0001193125-24-279061","cik":1055726,"company_name":"INOVIO PHARMACEUTICALS, INC.","ticker":"INO","form_type":"8-K","filed_at":"2024-12-16T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Inovio prices $30M public offering of 10M shares and warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["10M shares at $3.00/share plus warrants to buy 10M shares at $3.76, 5-year term.","Gross proceeds $30M; net proceeds ~$27.6M after discounts and expenses.","Closing expected December 16, 2024, subject to customary conditions.","Warrants include 4.99% beneficial ownership limitation (up to 9.99% on election).","Oppenheimer & Co. and Citizens JMP joint book-runners; Stephens Inc. lead manager."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":106543834.404,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":186288,"accession_number":"0001055726-24-000053","cik":1055726,"company_name":"INOVIO PHARMACEUTICALS, INC.","ticker":"INO","form_type":"8-K","filed_at":"2024-11-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Inovio Q3 net loss $25.2M; INO-3107 BLA on track for mid-2025 submission","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $25.2M ($0.89/share) vs $33.9M loss in Q3 2023; R&D expense $18.7M, G&A $8.6M.","Cash, equivalents and short-term investments $84.8M at Sept 30, 2024; cash runway into Q3 2025.","INO-3107 Phase 1/2 data: 81% of 32 patients had fewer surgeries; 28% had zero surgeries post-treatment.","All non-device BLA modules for INO-3107 on track for completion by year-end 2024; BLA submission targeted mid-2025.","Advancing Phase 3 plan for INO-3112 in HPV+ throat cancer; Phase 2 Ebola vaccine booster trial in FDA discussions."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.35,"consensus_revenue_estimate":null,"consensus_revenue_actual":100762.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":106543834.404,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":202911,"accession_number":"0001193125-24-199331","cik":1055726,"company_name":"INOVIO PHARMACEUTICALS, INC.","ticker":"INO","form_type":"8-K","filed_at":"2024-08-13T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"INOVIO enters $60M at-the-market equity distribution agreement with Oppenheimer","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sales agreement enables INOVIO to sell up to $60M of common stock via Oppenheimer as agent.","Commission of up to 3% of gross proceeds; INOVIO may suspend or terminate offering at any time.","Shares sold under existing S-3 registration statement; proceeds for general corporate purposes.","No obligation to sell any shares; sales are at INOVIO's sole discretion and subject to market conditions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":106543834.404,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":202910,"accession_number":"0001193125-24-197065","cik":1055726,"company_name":"INOVIO PHARMACEUTICALS, INC.","ticker":"INO","form_type":"8-K","filed_at":"2024-08-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Inovio Q2 net loss $32.2M; INO-3107 BLA submission delayed to mid-2025 due to device manufacturing issue","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $32.2M ($1.19/share) vs $35.5M ($1.61/share) in Q2 2023; revenue not disclosed.","Cash, equivalents and short-term investments $110.4M; cash runway estimated into Q3 2025.","BLA submission for lead candidate INO-3107 (RRP) delayed to mid-2025 due to manufacturing issue with disposable device component.","Appointed Steve Egge as Chief Commercial Officer; submitted Phase 3 trial design for INO-3112 to European regulators.","Raised $33.2M net in April 2024 stock/warrant offering."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.48,"consensus_revenue_estimate":null,"consensus_revenue_actual":100762.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":106543834.404,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":219115,"accession_number":"0001193125-24-148076","cik":1055726,"company_name":"INOVIO PHARMACEUTICALS, INC.","ticker":"INO","form_type":"8-K","filed_at":"2024-05-28T23:59:59+00:00","items":["5.02","5.07"],"status":"ready","headline":"Inovio grants performance-based RSUs tied to INO-3107 milestones; stockholders re-elect board","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CEO Shea receives 33,200 target PSUs; CFO Kies and CSO Humeau each receive 8,900 target PSUs.","Up to 70% of PSUs vest on INO-3107 milestones (FDA approval, launch, market share, sales) by 2025-2027.","Remaining 30% vest on relative TSR vs. Russell 2000 Biotech index June 2024-Dec 2027 (50%-150% of target).","Stockholders ratified Ernst & Young as auditor (11.1M for) and approved non-binding say-on-pay (3.0M for).","All eight director nominees elected with votes ranging 3.1M-3.8M for."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":106543834.404,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":219114,"accession_number":"0001193125-24-137228","cik":1055726,"company_name":"INOVIO PHARMACEUTICALS, INC.","ticker":"INO","form_type":"8-K","filed_at":"2024-05-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Inovio Q1 net loss narrows to $30.5M; BLA for INO-3107 on track for H2 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["BLA submission for INO-3107 (recurrent respiratory papillomatosis) on track for H2 2024 under accelerated approval pathway.","Phase 3 trial of INO-3112 + LOQTORZI for HPV-related throat cancer advancing; FDA feedback received.","Net loss $30.5M ($1.31/sh) vs $40.6M ($1.89/sh) in Q1 2023; R&D expenses fell to $20.9M.","Cash & equivalents $105.6M at Mar 31, 2024; April offering raised net ~$33.2M; cash runway into Q3 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.31,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":106543834.404,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":219113,"accession_number":"0001193125-24-099067","cik":1055726,"company_name":"INOVIO PHARMACEUTICALS, INC.","ticker":"INO","form_type":"8-K","filed_at":"2024-04-17T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Inovio priced ~$36M underwritten offering of common stock and pre-funded warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Priced 2,536,258 shares at $7.693/share and pre-funded warrants for 2,135,477 shares at $7.692/warrant.","Gross proceeds ~$36M; net proceeds ~$33.2M after underwriting discounts and expenses.","Offering led by Deep Track Capital; closes on or about April 18, 2024.","Oppenheimer & Co. and Citizens JMP Securities acting as joint book-running managers."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":106543834.404,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":238994,"accession_number":"0001193125-24-015380","cik":1055726,"company_name":"INOVIO PHARMACEUTICALS, INC.","ticker":"INO","form_type":"8-K","filed_at":"2024-01-25T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Inovio Pharmaceuticals effects 1-for-12 reverse stock split effective January 24, 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Every 12 issued and outstanding shares combined into 1 share; par value unchanged at $0.001.","Fractional shares not issued; stockholders entitled to fractional shares receive cash based on Jan 24 closing price.","Authorized shares of common stock remain at 600,000,000; no reduction.","Proportionate adjustments made to stock options, Series C Convertible Preferred Stock, and equity incentive plans."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":106543834.404,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":238993,"accession_number":"0001193125-24-007674","cik":1055726,"company_name":"INOVIO PHARMACEUTICALS, INC.","ticker":"INO","form_type":"8-K","filed_at":"2024-01-12T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Inovio shareholders approve reverse stock split at ratios from 1:10 to 1:50","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["146,265,973 shares (53.6%) present; reverse split approved with 96,534,629 For vs 48,857,255 Against.","Board authorized to implement split at any time within one year of Jan 12, 2024 special meeting.","Split ratio range 1-for-10 to 1-for-50, exact ratio to be determined by Board later.","Adjournment proposal also approved (106,842,257 For) to allow additional solicitation if needed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":106543834.404,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":256484,"accession_number":"0001193125-23-274515","cik":1055726,"company_name":"INOVIO PHARMACEUTICALS, INC.","ticker":"INO","form_type":"8-K","filed_at":"2023-11-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"INOVIO gets FDA breakthrough therapy for INO-3107; BLA on accelerated path without Phase 3 trial","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA granted Breakthrough Therapy designation for INO-3107 to treat Recurrent Respiratory Papillomatosis (RRP).","FDA confirmed Phase 1/2 trial data can support BLA submission under accelerated approval; no Phase 3 required.","Cash, cash equivalents and short-term investments of $167.5M as of September 30, 2023.","INOVIO planning to submit BLA under accelerated approval; type B meeting requested for Q4 2023.","Commercialization strategy accelerated for potential earlier launch of INO-3107 if approved."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":106543834.404,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":256483,"accession_number":"0001193125-23-269347","cik":1055726,"company_name":"INOVIO PHARMACEUTICALS, INC.","ticker":"INO","form_type":"8-K","filed_at":"2023-11-02T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Inovio receives 180-day Nasdaq extension for minimum bid; stock transferred to Capital Market","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Extension to April 29, 2024 to achieve $1.00 closing bid for 10 consecutive days.","Common stock transferred from Nasdaq Global Market to Capital Market effective Nov 2, 2023.","Failure to comply by April 29 may lead to delisting; company may appeal the determination.","Company will consider reverse stock split among options to regain compliance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":106543834.404,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":256482,"accession_number":"0001193125-23-253450","cik":1055726,"company_name":"INOVIO PHARMACEUTICALS, INC.","ticker":"INO","form_type":"8-K","filed_at":"2023-10-10T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"INOVIO gets FDA nod to use Phase 1/2 data for INO-3107 BLA under accelerated approval; Phase 3 waived","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA confirmed that completed Phase 1/2 trial data for INO-3107 in RRP can support BLA under accelerated approval; previously planned Phase 3 trial no longer required.","Confirmatory trial must be initiated before BLA submission; design not yet finalized.","If approved, INO-3107 would be first DNA medicine in the US and INOVIO's first commercial product.","Phase 1/2 results: 81.3% (26/32) of patients had fewer surgical interventions; median reduction of 3 surgeries; strong T-cell immune response with durable memory.","Cash runway guidance may change; company plans to provide updated cash guidance on Q3 2023 earnings call in November."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":106543834.404,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":273877,"accession_number":"0001193125-23-207397","cik":1055726,"company_name":"INOVIO PHARMACEUTICALS, INC.","ticker":"INO","form_type":"8-K","filed_at":"2023-08-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Inovio Q2 net loss $35.5M; stops VGX-3100 cervical program, cuts 30% staff","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $35.5M ($0.13 per share) on revenue of $226K; cash, equivalents & short-term investments $194.9M.","Ceasing U.S. development of VGX-3100 for cervical HSIL after biomarker analysis; shifting focus to INO-3107 Phase 3 for RRP targeted for Q1 2024.","Reducing workforce by 58 employees (30%) for ~$9.9M annual savings; cash runway extended into Q3 2025.","R&D expenses fell to $23.7M from $56.5M; G&A dropped to $13.5M from $48.5M YoY, partly due to lower COVID-related costs and litigation settlement.","ApolloBio continues VGX-3100 Phase 3 for cervical HSIL in China; INOVIO exploring anal HSIL and other pipeline candidates."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.29,"consensus_revenue_estimate":null,"consensus_revenue_actual":340914.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":106543834.404,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":273876,"accession_number":"0001193125-23-199683","cik":1055726,"company_name":"INOVIO PHARMACEUTICALS, INC.","ticker":"INO","form_type":"8-K","filed_at":"2023-08-01T23:59:59+00:00","items":["2.05"],"status":"ready","headline":"Inovio cuts 30% of workforce (58 employees) in reorganization plan; expects $2.1M charge, $9.9M annual savings","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reduction in force of 58 employees (~30% of full-time employees) committed on July 31, 2023.","One-time pre-tax charge of ~$2.1M in Q3 2023 mainly for severance and benefits.","Expects annual cost savings of ~$9.9M from the restructuring.","Cash payments for severance expected by October 31, 2023; charges incurred by Sept 30, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":106543834.404,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":290970,"accession_number":"0001193125-23-173847","cik":1055726,"company_name":"INOVIO PHARMACEUTICALS, INC.","ticker":"INO","form_type":"8-K","filed_at":"2023-06-23T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Inovio settles derivative litigation; court preliminarily approves governance reforms and $1.175M fee award","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Court preliminarily approved settlement of derivative lawsuit alleging misleading statements on COVID-19 vaccine INO-4800.","Settlement includes corporate governance reforms and $1,175,000 payment for plaintiffs' attorneys' fees, subject to court approval.","Final settlement hearing scheduled for October 11, 2023.","Defendants deny wrongdoing; settlement is without admission of liability.","Governance reforms address internal controls and oversight deficiencies alleged in complaints."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":106543834.404,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":290969,"accession_number":"0001193125-23-148122","cik":1055726,"company_name":"INOVIO PHARMACEUTICALS, INC.","ticker":"INO","form_type":"8-K","filed_at":"2023-05-18T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Inovio shareholders approve 2023 Omnibus Incentive Plan; elect directors with notable withhold for Zoth","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders approved the 2023 Omnibus Incentive Plan (14M new shares plus prior plan returning shares).","All eight director nominees elected; Lota Zoth received 36.4M withheld vs 57.4M votes for.","Ratification of Ernst & Young as independent auditor for FY2023: 155.6M for, 4.0M against.","Non-binding say-on-pay passed (60.4M for, 32.2M against); annual frequency selected for future votes.","Board determined to hold advisory votes on executive compensation every year going forward."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":106543834.404,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":290968,"accession_number":"0001193125-23-140755","cik":1055726,"company_name":"INOVIO PHARMACEUTICALS, INC.","ticker":"INO","form_type":"8-K","filed_at":"2023-05-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"INOVIO Q1 2023 net loss $40.6M; VGX-3100 misses in biomarker population","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $40.6M ($0.16/sh) vs $79.1M ($0.36) in Q1 2022; revenue $115K vs $199K.","Cash and equivalents $223.8M as of March 31; runway projected into Q1 2025.","Phase 3 VGX-3100 for cervical HSIL missed primary endpoint in biomarker population but achieved statistical significance in all-participants.","INO-3107 for RRP: 10 of 11 (91%) patients saw reduction in surgical interventions; well-tolerated.","Appointed Dr. Cheryl Elder as SVP Regulatory Affairs."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.16,"consensus_revenue_estimate":null,"consensus_revenue_actual":114943.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":106543834.404,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":311803,"accession_number":"0001193125-23-056363","cik":1055726,"company_name":"INOVIO PHARMACEUTICALS, INC.","ticker":"INO","form_type":"8-K","filed_at":"2023-03-01T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Inovio Q4 net loss $54.5M; VGX-3100 Phase 3 trial fails primary endpoint in biomarker group","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $54.5M ($0.22 per share) for Q4 2022; full year net loss $279.8M ($1.17 per share).","Cash and short-term investments $253M as of Dec 31, 2022; cash runway projected into Q1 2025.","REVEAL2 Phase 3 trial of VGX-3100 did not meet primary endpoint in biomarker-selected population (p=0.115); but achieved statistical significance in all-participants population (p=0.001).","Positive Phase 1/2 data for INO-3107 in RRP: median decrease of 3 surgical interventions; 91% of patients saw reduction.","Positive Phase 1b data for INO-4201 as Ebola booster: 100% of treated participants boosted humoral responses."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.17,"consensus_revenue_estimate":null,"consensus_revenue_actual":10262268.0,"consensus_period":"2022-FY","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":106543834.404,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":311802,"accession_number":"0001193125-23-019738","cik":1055726,"company_name":"INOVIO PHARMACEUTICALS, INC.","ticker":"INO","form_type":"8-K","filed_at":"2023-01-31T23:59:59+00:00","items":["2.05","7.01","8.01","9.01"],"status":"ready","headline":"Inovio cuts 11% of workforce, expects $4.3M annual savings; securities class action settled for $44M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reduced headcount by 24 employees (11% of full-time staff); one-time charge of $1.1M in Q1 2023.","Expected annual savings of ~$4.3M from reorganization and prior program discontinuations.","Court granted final approval of $44M securities class action settlement: $30M cash (paid by insurers) plus $14M in stock (initially 7M shares; <5% of outstanding).","Key data readouts expected Q1 2023 for INO-3107 (RRP) and VGX-3100 (cervical HSIL) trials.","Restructuring redirects resources to lead DNA medicine candidates; 2022 Q4 results planned for March 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":106543834.404,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":330365,"accession_number":"0001193125-22-280159","cik":1055726,"company_name":"INOVIO PHARMACEUTICALS, INC.","ticker":"INO","form_type":"8-K","filed_at":"2022-11-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"INOVIO Q3 net loss narrows to $0.15/sh; cash runway into Q1 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 2022 revenue of $9.2M vs $292K in Q3 2021, driven by DoD contract.","Net loss $37.8M ($0.15/sh) vs $60.2M ($0.29/sh) prior year; OpEx down to $44.9M.","Cash and investments $281.9M; guidance extended to early 2025 with ~$45M Q4 cash burn.","Discontinued internal INO-4800 heterologous COVID-19 booster; redeploying savings to other programs.","Positive interim INO-3107 data: median 3 fewer RRP surgeries; 29% needed no intervention in 52 weeks."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.96,"consensus_revenue_estimate":null,"consensus_revenue_actual":10137602.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":106543834.404,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":347918,"accession_number":"0001193125-22-216168","cik":1055726,"company_name":"INOVIO PHARMACEUTICALS, INC.","ticker":"INO","form_type":"8-K","filed_at":"2022-08-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Inovio reports Q2 net loss $108.5M, extends cash runway into Q3 2024 via restructuring; appoints new CMO","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $108.5M ($0.46 per share) vs $82.1M loss a year ago; revenue $784K (up from $273K).","Operating expenses $104.9M, up from $83.5M; includes $14M non-cash litigation settlement and $6.9M severance.","Cash & investments $348.1M at June 30; expects cash burn ~$73M in Q3, runway into Q3 2024.","Restructuring: 18% workforce reduction, 86% contractor cut; expects 30% OpEx reduction; $1.6M charge in Q3.","Appointed Dr. Michael Sumner as CMO; positive Phase 1/2 data for INO-5401 in GBM at ASCO."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.83,"consensus_revenue_estimate":null,"consensus_revenue_actual":983469.0,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":106543834.404,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":347917,"accession_number":"0001193125-22-196671","cik":1055726,"company_name":"INOVIO PHARMACEUTICALS, INC.","ticker":"INO","form_type":"8-K","filed_at":"2022-07-19T23:59:59+00:00","items":["2.05","7.01","9.01"],"status":"ready","headline":"INOVIO cuts 18% workforce (55 employees) and 86% of contractors to extend cash runway to Q3 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Headcount reduced by 55 employees (18% of full-time staff) and 86% of contractor agreements terminated.","Expected to reduce operating expenses by ~30% over 18 months; cash runway extended into Q3 2024.","One-time pre-tax charge of $1.6 million in Q3 2022; cash payments substantially completed by Sept 30, 2022.","Focus shifts to heterologous boost strategy for COVID-19 vaccine (INO-4800) and HPV programs; key data readouts later in 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":106543834.404,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":364474,"accession_number":"0001193125-22-153110","cik":1055726,"company_name":"INOVIO PHARMACEUTICALS, INC.","ticker":"INO","form_type":"8-K","filed_at":"2022-05-17T23:59:59+00:00","items":["5.02","5.07"],"status":"ready","headline":"Inovio appoints CEO Shea to board; shareholders approve auditor and exec compensation vote","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["CEO Jacqueline Shea appointed to board following May 16, 2022 annual meeting; term until 2023 annual meeting.","All seven director nominees elected; highest votes for David Weiner (53.2M), lowest for Lota Zoth (48.1M for).","Ratification of Ernst & Young as auditor passed with 109.6M for, 6.7M against, 1.4M abstain.","Advisory 'say-on-pay' vote passed with 40.8M for, 16.9M against, 0.7M abstain; broker non-votes 59.2M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":106543834.404,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":364473,"accession_number":"0001193125-22-146350","cik":1055726,"company_name":"INOVIO PHARMACEUTICALS, INC.","ticker":"INO","form_type":"8-K","filed_at":"2022-05-10T23:59:59+00:00","items":["2.02","5.02","7.01","9.01"],"status":"ready","headline":"Inovio Q1 net loss $79.1M ($0.36/share); CEO Kim resigns, Shea appointed; discontinues INNOVATE trial","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Net loss $79.1M ($0.36/share) vs $54.4M ($0.27) in Q1 2021; revenue $199K.","CEO J. Joseph Kim resigns; Jacqueline Shea (former COO) appointed President and CEO; Shea base salary $700K.","Phase 3 INNOVATE trial for COVID-19 vaccine discontinues; prioritize heterologous booster strategy.","VGX-3100 BLA for cervical HSIL not expected in 2023; REVEAL2 amended to biomarker-selected population.","Cash and investments $360.4M at Mar 31, 2022, down from $401.3M at Dec 31, 2021."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":106543834.404,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":402011,"accession_number":"0001193125-21-313502","cik":1055726,"company_name":"INOVIO PHARMACEUTICALS, INC.","ticker":"INO","form_type":"8-K","filed_at":"2021-10-29T23:59:59+00:00","items":["1.02"],"status":"ready","headline":"Inovio loses AstraZeneca-partnered cancer vaccine pact; reacquires INO-3112 rights","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["MedImmune (AstraZeneca R&D) terminated INO-3112/MEDI0457 collaboration effective Oct 28, 2021.","Inovio reacquires all rights to INO-3112; forfeits future milestone payments and royalties.","MedImmune continues Phase 2 HNSCC trial; final data cut-off completed, study report by end of 2022.","Revenue from the agreement was minimal: $33k in H1 2021, $171k in 2020, $2M in 2019.","Company states it is not substantially dependent on the terminated collaboration agreement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":106543834.404,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":402010,"accession_number":"0001193125-21-310286","cik":1055726,"company_name":"INOVIO PHARMACEUTICALS, INC.","ticker":"INO","form_type":"8-K","filed_at":"2021-10-28T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"Inovio's COVID-19 vaccine INO-4800 selected for WHO Solidarity Trial Vaccines Phase 3","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["WHO confirmed Oct 26, 2021 that INO-4800 is one of two vaccines in large international Phase 3 Solidarity Trial.","Selected by independent advisory group from ~20 candidate vaccines; two more vaccines may enter later.","Trial recruiting volunteers at over 40 sites across Colombia, Mali, and the Philippines.","Inovio also conducting separate global Phase 3 INNOVATE trial with partner Advaccine."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":106543834.404,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}